An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A group of experts is urging doctors to check patients for eating disorders before starting them on GLP-1 medications. These drugs—now widely used for diabetes and weight loss—can change appetite and body weight. The experts worry that without screening, people with current or past eating disorders might be harmed or have their conditions masked. GLP-1s are a class of medicines that copy a natural gut signal called glucagon-like peptide-1. In everyday terms, they make you feel less hungry and slow how fast food leaves your stomach. You may have heard of brand names like Ozempic and Wegovy; those are examples of GLP-1 drugs or closely related medicines. Doctors prescribe them for type 2 diabetes and, increasingly, for weight management. The experts’ recommendation is based on clinical experience, case reports, and the known effects of the drugs—not on a single large trial proving harm in people with eating disorders. They point out that the appetite-suppressing effects could either hide disordered eating or interact badly with behaviors like restrictive eating, bingeing, or purging. The concern also includes the psychological impact of rapid weight change and how that could trigger relapse. The evidence cited tends to be observational and precautionary; it flags risk rather than documenting widespread, confirmed harm. Why this matters is practical. Lots of people are trying GLP-1 drugs now, and many patients may have undiagnosed or recovered-from eating disorders. Screening would help doctors decide who needs extra monitoring, who should be referred to a mental health or eating-disorder specialist, and when to avoid or pause the medication. For patients, it could mean safer care and better coordination between medical and mental-health teams. There are important caveats. Screening doesn’t mean denying treatment automatically. It’s about identifying risk so clinicians can make informed choices. The scientific record still has gaps: we don’t have large, definitive studies showing exactly how common problems are or which patients are most vulnerable. GLP-1 drugs have other side effects too—nausea, stomach upset, and in rare cases more serious issues—and they are prescription medicines that should be started under medical supervision. If someone has a history of an eating disorder, they should tell their doctor and expect closer follow-up. Bottom line: Experts recommend checking for eating-disorder history before starting GLP-1 drugs so risks can be spotted and managed, but more research is needed to know how big the problem really is.
Source: News-Medical